Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04112615
Other study ID # IRAS: 271364
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date February 17, 2020
Est. completion date June 15, 2020

Study information

Verified date February 2021
Source Entia Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Co-design of a home-based haemoglobin monitoring system with participants with anaemia of chronic kidney disease.


Description:

The device/monitoring system being developed measures the haemoglobin and haematocrit levels in blood from a single drop of blood. By measuring these blood parameter, participants are able to monitor their haemoglobin level at home. The use of the device will take place in the participant's home to simulate what the investigators believe will be the ideal location for people who would prefer to self-manage their condition. This study is a unique opportunity to gain feedback on the future design and development of a home-based monitoring system through user evaluation. As this is an adaptive/ iterative study design, this will give the Sponsor the opportunity to make changes to the user interface and user platform based on the feedback received from the end user.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 15, 2020
Est. primary completion date June 15, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years and older
Eligibility Inclusion criteria: For patients: - Adequate English to participate in focus groups without an interpreter - Patients of the study site who are currently undergoing treatment for anaemia of CKD - Patients willing to participate in at least one or more 60-minute and ideally 90-minute focus groups at the designated study location, time and date. - Patients capable of providing informed consent before attending the first focus group For carers: - Should be the primary carer nominated by a patient who fulfils the inclusion criteria, this includes parents of affected children - Should be willing to participate in at least 60-minute and ideally 90-minute focus groups at the designated study location, time and date. - Carers can only participate in the study with the patient he/she is caring for. The patient has also to be involved in the study - Carers need to be capable of providing informed consent before attending the first focus group For healthcare professionals: - All clinicians need to be current employees of the study site - Doctors need to be employed at Specialist Registrar, Fellow or Consultant Level - Nurses of all grades are invited to participate but ideally need to have had some involvement in the outpatient care of CKD patients with anaemia All participants: - Should be willing to have the session's recorded audio, transcripts and analysed data from the focus groups shared with Entia. - should be willing to attend multiple 60 to 90 minute focus groups. - should be willing for unidentifiable photos and video footage to be taken during the interview. - Participants attending focus groups later in the development process must be comfortable consenting to finger prick testing/ assessing the ease of use of the test disposable Exclusion criteria: Patients: - Does not have adequate English to participate in focus group interviews without an interpreter. - Patients of the study site who are not currently undergoing treatment or have previously undergone treatment within the past 12 months. - Patients not willing to participate in at least 60-minute and ideally 90-minute focus group discussion at the designated study location, time and date. - Participant not capable of providing consent or have a suitable, legally acceptable representative present to provide consent before the focus group interview. For carers: - Is not the nominated primary carer of a patient who fulfils the inclusion criteria, this includes parents of affected children - Not paired with a patient that is involved in the study - Carers not willing to participate in at least a 60-minute and ideally 90-minute focus group discussion at the designated study location, time and date. For healthcare professionals: None.

Study Design


Intervention

Device:
Blood measurement
Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.

Locations

Country Name City State
United Kingdom Hull University Teaching Hospitals NHS Trust Hull

Sponsors (1)

Lead Sponsor Collaborator
Entia Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Qualitative capture of user feedback- focus groups User feedback gathered from participants using the blood measurement device will be used to inform the changes necessary to develop a successful home-based haemoglobin monitoring system.
Feedback will be analysed based on framework analysis.
12 months
See also
  Status Clinical Trial Phase
Completed NCT03325621 - Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients Phase 1/Phase 2
Completed NCT02198495 - Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients Phase 4
Suspended NCT03193073 - Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient N/A
Completed NCT02581124 - Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease Phase 1
Completed NCT02268994 - KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD Phase 3
Completed NCT04543812 - PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD Phase 3
Recruiting NCT05900635 - Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients Phase 4
Completed NCT04667533 - Desidustat in the Treatment of Chemotherapy Induced Anemia Phase 1
Completed NCT03731741 - Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients? Phase 2
Completed NCT02787824 - Periodic Versus Continuous IV Iron Supplementation in HD Patients Phase 4
Completed NCT03431623 - CKD-11101 Phase 3 SC Study Phase 3
Completed NCT01971164 - Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease Phase 1
Recruiting NCT01532349 - Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease Phase 2
Completed NCT05698420 - Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients
Completed NCT03427801 - Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease
Recruiting NCT03521713 - To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) Phase 3
Active, not recruiting NCT02754167 - Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients Phase 1/Phase 2
Completed NCT02805244 - Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis Phase 1
Completed NCT03428594 - CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis Phase 3
Recruiting NCT06463236 - Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients N/A